List of Excipients in API olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg
✉ Email this page to a colleague
Excipients in ANDA-approved (generic) drugs containing olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg
Detailed excipient profiles for olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg
Excipient focus: CROSCARMELLOSE SODIUM
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: STARCH, CORN
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SUCCINIMIDYL-4-(N-MALEIMIDOMETHYL)CYCLOHEXANE-1-CARBOXYLATE
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing SUCCINIMIDYL-4-(N-MALEIMIDOMETHYL)CYCLOHEXANE-1-CARBOXYLATE
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing SUCCINIMIDYL-4-(N-MALEIMIDOMETHYL)CYCLOHEXANE-1-CARBOXYLATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg | 13668-397 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
